MedPath

Tagged News

MUSC Researchers Engineer CHAR-Tregs to Target Organ Rejection with Precision Immunosuppression

Precision Medicine
  • Medical University of South Carolina researchers have developed genetically engineered regulatory T-cells equipped with chimeric anti-HLA antibody receptors (CHARs) that can precisely target and neutralize antibody-producing B-cells responsible for organ rejection.
  • The CHAR-Treg approach demonstrated significant efficacy in laboratory tests using cells from dialysis patients with kidney rejection history, dramatically reducing anti-HLA-A2 antibody levels.
  • This targeted immunosuppression strategy could revolutionize transplant medicine by reducing rejection risk without broadly suppressing the immune system, particularly benefiting pre-sensitized patients who face limited donor organ eligibility.
  • The research represents the first application of genetically modified immune cell technology to suppress rather than stimulate immune responses in the context of organ transplantation.

KIFFIK Biomedical Strengthens Leadership with Strategic Appointments to Advance Interstitial Fluid Diagnostics

Precision MedicineOncology
  • KIFFIK Biomedical appointed Rene Veloso as Chief Investment Officer to secure capital investments for interstitial fluid real-time monitoring applications in cancer and other diseases.
  • Dr. Reginald Swift, CEO of Rubix Life Sciences, joined as fractional Chief Scientific Officer to shape clinical operations and ensure R&D activities meet highest scientific standards.
  • The company's proprietary KIFFIK EXP platform offers needle-free, real-time diagnostics for oncology and therapeutic monitoring through interstitial fluid-based biomarker detection.
  • KIFFIK previously established a strategic partnership with Rubix Life Sciences to advance next-generation ISF extraction technology using aptamer-based precision medicine approaches.

Lantern Pharma Reports Complete Responses in Two Cancer Trials, Advances AI-Driven Pipeline

AIOncologyPrecision Medicine
  • Lantern Pharma achieved complete responses in two separate clinical trials, with LP-300 showing complete tumor response in a 70-year-old never-smoker lung cancer patient and LP-284 demonstrating complete metabolic response in a heavily pretreated lymphoma patient.
  • The company successfully completed enrollment of 65 patients in its LP-184 Phase 1a trial and established maximum tolerated dose and recommended Phase 2 dose, positioning the drug candidate for advancement to Phase 1b/2 studies.
  • Lantern narrowed its Q2 2025 GAAP net loss to $0.40 per share from $0.46 per share in Q2 2024, while maintaining disciplined cost management with $15.9 million in cash providing runway through mid-2026.

Study of LP-184 in Patients with Advanced Solid Tumors

NCT05933265RecruitingPhase 1
Lantern Pharma Inc.
Posted 6/9/2023

Caris Life Sciences Study Reveals Optimal Sequencing Strategy for Antibody-Drug Conjugates in HER2-Negative Breast Cancer

Precision MedicineReal World Evidence
  • Caris Life Sciences published a real-world evidence study in Breast Cancer Research comparing trastuzumab deruxtecan and sacituzumab govitecan in over 4,000 HER2-negative breast cancer patients.
  • The study found that trastuzumab deruxtecan demonstrated superior treatment duration for hormone receptor-positive patients, while sacituzumab govitecan showed better first-line results in HR-negative and HER2-null tumors.
  • Both antibody-drug conjugates provided comparable benefits in triple-negative breast cancer patients, highlighting the importance of personalized treatment strategies based on tumor subtype.
  • The research addresses the absence of head-to-head clinical trials between the two most commonly used ADCs in breast cancer treatment.

Oxford BioDynamics Partners with Google Cloud to Scale AI-Powered 3D Genomic Analytics Platform

Precision Medicine
  • Oxford BioDynamics has partnered with Google Cloud to expand its 3D genomic biomarker technology capabilities through cloud-based infrastructure and AI-powered analytics.
  • The collaboration will enable OBD to scale its proprietary EpiSwitch knowledge base and analytical tools to provide high-throughput genomic analytics to pharmaceutical and biotechnology partners.
  • Google Cloud's infrastructure will support containerized applications, AI/ML tools integration, and secure data processing pipelines that meet healthcare compliance standards.
  • The partnership aims to accelerate access to predictive genomic insights for drug development and diagnostics through real-time 3D genomics analysis.

Tahoe Therapeutics Secures $30M to Create World's Largest Single-Cell Dataset for AI-Driven Drug Discovery

AIPrecision MedicineDrug Discovery
  • Tahoe Therapeutics raised $30 million in Series A funding led by Amplify Partners to build a one billion single-cell datapoint dataset for training Virtual Cell Models.
  • The company's previous Tahoe-100M dataset has been downloaded nearly 100,000 times and already led to discovery of promising therapeutic candidates for major cancer subtypes.
  • The new dataset will map one million drug-patient interactions and aims to reduce clinical trial failure rates while accelerating precision medicine development.
  • Tahoe plans to select a single strategic partner to access the dataset and collaborate on developing the first medicines powered by virtual cell models.

FDA Approves Boehringer Ingelheim's HERNEXEOS as First-in-Class HER2 TKI for Rare Lung Cancer Subset

Drug ApprovalPrecision Medicine
  • The FDA granted accelerated approval to HERNEXEOS (zongertinib) in August 2025, marking the first oral therapy specifically targeting HER2 tyrosine kinase domain mutations in non-squamous NSCLC.
  • Clinical data demonstrated a 75% objective response rate in previously untreated patients and 96% disease control rate, with a more manageable safety profile compared to existing treatments.
  • The approval addresses an aggressive cancer subset affecting 2-4% of lung cancer patients and represents a significant advancement in precision oncology for underserved populations.

Dana-Farber Researchers Develop SWIFT-seq Blood Test to Replace Bone Marrow Biopsies in Multiple Myeloma

Precision Medicine
  • Researchers at Dana-Farber Cancer Institute have developed SWIFT-seq, a blood test that uses single-cell sequencing to profile circulating tumor cells and could replace painful bone marrow biopsies for multiple myeloma diagnosis and monitoring.
  • The test successfully captured circulating tumor cells in 90% of patients with MGUS, SMM, and multiple myeloma, with detection rates of 95% in SMM patients and 94% in newly diagnosed multiple myeloma patients.
  • SWIFT-seq provides comprehensive genetic profiling, tumor growth assessment, and prognostic gene signatures from a single blood sample, offering superior accuracy compared to traditional FISH testing methods.
  • The breakthrough could transform patient care by enabling routine, non-invasive monitoring and risk stratification while providing novel insights into myeloma biology that may lead to new therapeutic approaches.

Kura Oncology's Ziftomenib Receives FDA Priority Review for NPM1-Mutant AML, PDUFA Date Set for November 2025

OncologyPrecision Medicine
  • Kura Oncology's lead asset ziftomenib has advanced to FDA Priority Review for relapsed/refractory NPM1-mutant acute myeloid leukemia, with a PDUFA date of November 30, 2025.
  • The KOMET-001 pivotal trial demonstrated a 23% complete remission rate in heavily pretreated, high-risk patients, with manageable safety profile and no significant cardiac safety issues.
  • Ziftomenib is the only menin inhibitor to receive both Priority Review and Breakthrough Therapy Designation for this indication, positioning it as a potential first-in-class treatment.
  • The company reported Q2 2025 collaboration revenue of $15.3 million, missing analyst expectations of $39.1 million, while maintaining $630.7 million in cash reserves extending runway into 2027.

Genetic Testing Reduces Severe Chemotherapy Side Effects by 42% in Gastrointestinal Cancer Patients

Precision Medicine
  • Pre-treatment genetic testing for DPYD and UGT1A1 variants reduced severe chemotherapy side effects from 65% to 38% in gastrointestinal cancer patients with genetic variants.
  • The precision medicine approach enabled doctors to tailor chemotherapy doses within one week, resulting in fewer treatment changes and discontinuations compared to standard dosing.
  • With nearly 290,000 Americans diagnosed with gastrointestinal cancers annually, researchers estimate this testing could prevent up to 1,300 deaths per year from chemotherapy toxicity.
  • The University of Pennsylvania study demonstrates that genetic screening is both feasible and critical for patient safety in cancer treatment.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.